US 7396664B2
· Daly et al.
· 2008
[cited by applicant]
US RE43612E
· Anderson et al.
· 2012
[cited by applicant]
US 9150867B2
· Maher, III et al.
· 2015
[cited by applicant]
US 9340591B2
· Sullenger et al.
· 2016
[cited by applicant]
US 20060105975A1
· Pendergast et al.
· 2006
[cited by applicant]
US 20110178161A1
· Trent et al.
· 2011
[cited by applicant]
US 20110197292A1
· Sullenger
· 2011
[cited by applicant]
US 20140348755A1
· Weng
· 2014
[cited by applicant]
US 20170165376A9
· Rich
· 2017
[cited by applicant]
US 20190359983A1
· O'Neill et al.
· 2019
[cited by applicant]
EP 1800695
· 2007
[cited by applicant]
WO 2002026932
· 2002
[cited by applicant]
WO 2004081021
· 2004
[cited by applicant]
WO 2007071777
· 2007
[cited by applicant]
WO 2009045545
· 2009
[cited by applicant]
WO 2014121256
· 2014
[cited by applicant]
WO 2014169049
· 2014
[cited by applicant]
Allerson, C. R. et al. “Fully 2′-Modified Oligonucleotide Duplexes with Improved in Vitro Potency and Stability Compared to Unmodified Small Interfering RNA.” J. Med. Chem 48 (2005): 901-904.
[cited by applicant]
Bates P Jet Al: “Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer”, Experimental and Molecular Pathology, Academic Press, US, vol. 86, No. 3, Jun. 1, 2009 (Jun. 1, 2009), pp…
[cited by applicant]
Becker et al., “Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application,” (2005) Thromb. Haemost. 93:1014-1020.
[cited by applicant]
Berenbaum et al., “Synergy, additivism and antagonism in immunosuppression. A critical review,” (1977) Clin Exp Immunol 28: 1-18.
[cited by applicant]
Champlin, R. E. et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 2000;95: 3996-4003.
[cited by applicant]
Chen et al., “Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA,” (2008) Mol. Ther. 16(2):333-42—Abstract.
[cited by applicant]
Cheng, Y, et al. “AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia”, Current Opinion in Molecular Therapeutics, Current Drugs,…
[cited by applicant]
Chu et al., “Aptamer mediated siRNA delivery,” (2006) Nucleic Acids Research 34(10):e73.
[cited by applicant]
Conrad, R.C. et al. “[20] In vitro selection of nucleic acid aptamers that bind proteins.” Methods in enzymology 267 (1996): 336-367.
[cited by applicant]
Dyke et al., “First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa act…
[cited by applicant]
Ellington et al., “In vitro selection of RNA molecules that bind specific ligands.” (1990) Nature 346:818-22.
[cited by applicant]
Extended European Search Report for European Patent Application No. 18853636.1, dated Nov. 10, 2021.
[cited by applicant]
Farokhzad et al., “Nanoparticle aptamer bioconjugates: A new approach for targeting prostate cancer cells,” (2004) Cancer Research 64:7668-7672.
[cited by applicant]
Gen Bank CR446327, CR 446327 XGC-tailbud Xenopus tropicalis cDNA clone TTbA054d215-mRNA sequence. GenBank Accession No. CR446327. Jun. 19, 2004. Retrieved from teh internent: URL:https://.ncbi.nlm.nih.gov/nucest/CR44632…
[cited by applicant]
Goldstein, Michael, et al. “Nucleolin mediates nucleosome disruption critical for DNA double-strand break repair.” Proceedings of the National Academy of Sciences 110.42 (2013): 16874-16879.
[cited by applicant]
International Search Report and Written Opinion for application PCT/US2018/050240.Mailed on Jan. 29, 2019 (17 pages).
[cited by applicant]
James et al., “A molecular imaging primer: modalities, imaging agents, and applications,” (2012) Physiol Rev 92 (2):897-965.
[cited by applicant]
Keefe, A. D., et al. (2010). Aptamers as therapeutics. Nature reviews Drug discovery, 9(7), 537-550.
[cited by applicant]
Khaled et al., “Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology,” (2005) Nano Letters 5(9):1797-1808.
[cited by applicant]
Labib, M. et al “Aptamer and Antisense-Mediated Two-Dimensional Isolation of Specific Cancer Cell Subpopulations” J. Am. Chem. Soc. 2016 138:2476-2479.
[cited by applicant]
Lai, Y.-T., et al. “A primer-free method that selects high-affinity single-stranded DNA aptamers using thermostable RNA ligase.” Analytical biochemistry 414.2 (2011): 246-253.
[cited by applicant]
Li, F. et al. “A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer”, Nature Communications, vol. 8, No. 1, Nov. 9, 2017.
[cited by applicant]
Li, N., et al. “Inhibition of cell proliferation by an anti-EGFR aptamer.” PloS one 6.6 (2011): e20299.
[cited by applicant]
Lupold et al., “Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen,” (2002) Cancer Research 62:4029-4033.
[cited by applicant]
Nimjee et al., “Aptamers as Therapeutics,” (2017) Annual review of pharmacology and toxicology 57:61-79.
[cited by applicant]
Nimjee et al., “Aptamers: an emerging class of therapeutics,” (2005) Annual review of medicine 56:555-83.
[cited by applicant]
Office Action for U.S. Appl. No. 16/645,762 dated Jun. 13, 2022.
[cited by applicant]
Osbourne. S.E. et al. “Nucleic acid selection and the challenge of combinatorial chemistry.” Chemical reviews 97.2 (1997): 349-370.
[cited by applicant]
Que-Gewirth, N.S. et al., “Gene therapy progress and prospects: RNA aptamers,” (2007) Gene Therapy 14 (4):283-291.
[cited by applicant]
Ray, P. et al. “Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells.” Nucleic acid therapeutics 22.5 (2012): 295-305.
[cited by applicant]
Restriction Requirement for U.S. Appl. No. 16/645,762, mailed Dec. 3, 2021.
[cited by applicant]
Reyes-Reyes, E. Merit, et al. “Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.” Molecular oncology 9.7 (2015): 1392-1405.
[cited by applicant]
Schlessinger, J. “Autoinhibition control.” Science 300.5620 (2003): 750-752.
[cited by applicant]
Tuerk et al., “Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase,” (1990) Science 249:505-10.
[cited by applicant]
White, R. et al., “Generation of Species Cross-reactive Aptamers Using Toggle SELEX,” (2001) Molecular Therapy 4 (6):567-573.
[cited by applicant]
White, R. R. et al., “Developing aptamers into therapeutics,” (2000) J. Clin. Investigation 106(8):929-934.
[cited by applicant]